Eli Lilly and Company

Threat Mitigation Lead - Network and Systems Attack Surface

United States

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Healthcare, CybersecurityIndustries

Requirements

Candidates should possess a Bachelor’s degree in computer science, Information Security, or a related field, or equivalent work experience, and a minimum of 5 years of experience in network and infrastructure security or cybersecurity. They must demonstrate a deep understanding of network and infrastructure security principles, along with experience in cybersecurity or related fields.

Responsibilities

As a Threat Mitigation Lead, the individual will be responsible for leading network and infrastructure security threat mitigation efforts to reduce security threats across network and infrastructure environments, collaborating with network and systems engineering and cyber teams to achieve threat mitigation objectives, partnering with network security experts and cyber leadership to prioritize identified security threats, providing guidance on mitigation activities, driving the implementation of practical mitigation actions, and contributing to the creation and execution of threat mitigation strategies. They will also work with network and infrastructure teams to promote best practices, continuously improve security practices, and encourage a security-aware culture, while supporting effort to improve metrics and reporting and ensuring visibility into ongoing threat mitigation efforts.

Skills

Infrastructure Security
EDR
SIEM
Firewalls
Network Security
Cybersecurity
Threat Mitigation
Cross-Functional Collaboration
Problem-Solving

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Key Metrics

Indianapolis, IndianaHeadquarters
1876Year Founded
$1,180.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.
Potential construction delays in Indiana could affect GLP-1 drug production timelines.
Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.
Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.
FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.
Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.
Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI